Table 3Clinical evidence summary: People with asthma vs control

OutcomesNo of Participants (studies) Follow upQuality of the evidence (GRADE)HR (95% CI)Anticipated absolute effects
Risk with ControlRisk difference with Asthma (95% CI)
Incidence of OSA

194187

(1 study)

⊕⊕⊝⊝

LOW2

due to risk of bias

HR 1.87

(1.61 to 2.17)1

3 per 1000

3 more per 1000

(from 2 more to 4 more)3

1

Model adjusted for age, sex and comorbidities of hypertension, diabetes, hyperlipidaemia, COPD, CAD, stroke, rhinitis, chronic sinusitis, GERD and obesity

2

Risk of bias was assessed using the QUIPS checklist. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

3

GC considered the clinical importance of the effect estimate for each analysis on a case by case basis, taking into consideration the increment of the risk factor and the outcome under study.

From: When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome

Cover of When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome
When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome: Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Evidence review A.
NICE Guideline, No. 202.
National Guideline Centre (UK).
Copyright © NICE 2021.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.